Metabolism Disorder TRIZ Cases

Targeted LDC mutations improve catalytic activity, proteolysis resistance, and low-pH stability to lower toxic BCAA levels in MSUD.

A FATP1-targeted peptide vaccine blocks fatty acid uptake to lower triglycerides, visceral fat, and liver fat without appetite suppression.

A waffle-like planar hydrogel distributes islet microtissues evenly to improve oxygen diffusion, support angiogenesis, and preserve insulin secretion.

Bypassing intestinal bacterial degradation, this parenteral formulation uses phosphatidylcholine and choline compounds to boost liver and brain delivery.

Co-transplanted CD34+ or parathyroid-derived cells improve extrahepatic islet graft vascularization, survival, and diabetes reversal.

Targeting RIOK2 expression and activity helps correct blood cell differentiation defects and expands treatment options for anemia and related disorders.

By scavenging lipid peroxidation products, 2-hydroxybenzylamine preserves SIRT3 activity and normalizes glutamine metabolism in PAH.

CHO-cell acid α-glucosidase with higher mannose-6-phosphate plus miglustat improves tissue uptake, stability, and dose efficiency in Pompe disease.

High-fat, high-fiber pet food balances ketosis, gut health, and low ash to reduce renal strain while staying palatable and durable.

Antibody modulation of the GDF15-GFRAL pathway helps relieve nausea and emesis and prevent weight loss across hard-to-treat conditions.

Blocking CXCR1/CXCR2 helps prevent mesangial expansion and podocyte injury, reducing albumin excretion in early diabetic nephropathy.

Using glycerophosphocholine in parenteral lipid emulsions improves choline stability and delivery while helping prevent hepatic steatosis.

Fine microcrystalline cellulose at 95 µm or less improves disintegration and dissolution in NEP inhibitor and ARB formulations affected by hygroscopicity.

Fatty acid-linked amylin derivatives reduce fibrillation at neutral pH while extending half-life and lowering dosing frequency.

Modified peptide analogues extend blood half-life and support weight loss and insulin release with fewer side effects and less frequent dosing.

A codon-optimized PKLR lentiviral cassette boosts erythroid expression while lowering insertional mutagenesis risk in PKD gene therapy.

Engineered Fc-modified immunoglobulins coengage FcγRIIb and target antigens to suppress calcium signaling in FcγRIIb+ cells.

Gradual weekly dose escalation of a GGG tri-receptor agonist improves glycemic control and weight management while limiting gastrointestinal adverse events.

Modified PCSK9 siRNA conjugates target hepatocytes to suppress gene expression, lower LDL-C, and address tolerability limits of current therapies.

Targeted amino acid substitutions and fatty acid conjugation extend GIP antagonist half-life while improving receptor selectivity and reducing off-target GPCR activation.

A GIPR-binding antagonist paired with a GLP-1 agonist improves sustained glucose and insulin management while reducing weight and liver steatosis.

Engineered or selected gut bacterial strains regulate bile salts and bile acids to alter lipid and steroid metabolism in metabolic disorders.

A multi-component hirudin supplement combines natural anticoagulant and lipid-lowering agents to reduce thrombin activity and blood lipids with fewer drug side effects.

Combining an FXR agonist with PPAR agonists or statins improves lipid and liver enzyme control when monotherapy is inadequate.

A myostatin-selective inhibitor paired with GLP-1 activation drives fat loss while preserving lean muscle mass and avoiding non-selective safety risks.

Small-molecule TGFβ, GSK3, and ROCK inhibition reprograms pancreatic cells into stem/progenitor cells without genetic modification.

Empagliflozin slows chronic kidney disease progression, reduces albuminuria, and lowers kidney failure risk in diabetic patients.

Cyclic SSTR2 antagonists boost glucagon secretion to prevent insulin-induced hypoglycemia and improve long-term blood glucose management.

An Fc-fused, disulfide-stabilized FGF21 variant extends half-life to reduce dosing frequency while improving metabolic and cardiovascular markers.

Using low-dose IL-2 selectively expands Tregs over effector T cells, reducing autoimmune inflammation while limiting disease aggravation.

Co-expressing a lysosomal enzyme with modified GlcNAc-1 phosphotransferase boosts phosphorylation, lysosomal uptake, and tissue delivery.

Rare hydroxylated and oxo fatty acids activate PPARs to improve lipid and sugar metabolism and broaden metabolic support beyond conventional fatty acids.

Selective triazolopyrimidine and imidazolopyrimidine ENPP1 inhibitors block cGAMP and ATP degradation to preserve immune activation in disease.

NaCl and dibasic sodium phosphate concentration tuning helps tirzepatide formulations keep shelf-life stability while improving injection site experience.

Combining an FXR agonist with statins or PPAR agonists improves lipid and liver enzyme control when single-agent therapy is inadequate.

Multiple folded chambers and a semipermeable membrane pack a high cell dose into a small implant footprint while maintaining nutrient exchange.

A pentadecanoic acid triglyceride promotes insulin secretion during hyperglycemia to improve blood glucose control without raising hypoglycemia risk.

Fixed-ratio GLP-1R and THRβ agonist combinations improve weight loss and liver outcomes while reducing dose-related gastrointestinal side effects.

Reversible peptides suppress HDAC5 phosphorylation plus GDF15 and ATF3 expression to reduce inflammation, fibrosis, and side effects.

Peptide sequence and cyclic-bridge tuning improves MC4R selectivity over MC1R, supporting weight loss while limiting hyperpigmentation.

Intramolecularly stapled co-agonist peptides stabilize alpha-helical structure to resist degradation, limit aggregation, and improve dosing.

Balanced GIP, GLP-1, and glucagon receptor agonism extends dosing intervals while improving glucose control, weight loss, and tolerability.

Selenocysteine substitution at A6 and A11 forms a diselenide bridge that resists insulin fibrillation and extends shelf life above room temperature.

By combining capsid proteins from multiple AAV serotypes, this case improves transduction while reducing neutralizing antibody response.

Gelsolin therapy addresses the lack of effective frailty treatment by improving survival while reducing muscle wasting, cachexia, and instability.

Local TNAP delivery into the periodontium promotes cementum repair, alveolar bone regeneration, and periodontal ligament reattachment.

A dual-action composition modulates blood coagulation in opposite directions, helping balance bleeding control and thrombosis risk.

Sequential enzymolysis and resin purification turn pea protein by-products into absorbable peptides that support blood glucose control.

Chemical modifications improve proteolytic stability and half-life in GLP-1/glucagon dual agonist peptides, enabling once-weekly dosing.

A polymer, penetrant, and surfactant formulation enables sustained skin delivery of glucose-control agents while limiting systemic side effects.